ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BNTC Benitec Biopharma Limited

8.50
0.60 (7.59%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Benitec Biopharma Limited NASDAQ:BNTC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 7.59% 8.50 8.50 9.20 9.46 8.1547 8.24 61,235 00:53:08

Report of Foreign Issuer (6-k)

09/11/2018 11:19am

Edgar (US Regulatory)


 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2018

(Commission File No. 001-37518)

 

Benitec Biopharma Limited

(Translation of registrant’s name into English)

 

Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes       No  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes       No  

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes       No  

 

 

 

 


 

EXHIBIT INDEX

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

Benitec Biopharma Limited

 

By:

/s/ Megan Boston

Name:

Megan Boston

Title:

Executive Director

Date: November 09, 2018

 

 

1 Year Benitec Biopharma Chart

1 Year Benitec Biopharma Chart

1 Month Benitec Biopharma Chart

1 Month Benitec Biopharma Chart

Your Recent History

Delayed Upgrade Clock